Publications

37 items matching your search terms.

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue

Nguyen, L. T.; Lo, C. S.; Fyrsta, M.; Nie, J.; Yam, J. Y.; Yen, P. H.; Le, M. X.; Hersey, K.; Kenk, M.; Crumbaker, M.; Fleshner, N.; Kulkarni, G.; Hamilton, R.; Jewett, M.; Finelli, A.; Evans, A.; Sweet, J.; Ohashi, P. S.; Joshua, A. M.

Prostate Cancer 2022 :6499344, 2022 10.1155/2022/6499344

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Emmett, L.; Subramaniam, S.; Joshua, A. M.; Crumbaker, M.; Martin, A.; Zhang, A. Y.; Rana, N.; Langford, A.; Mitchell, J.; Yip, S.; Francis, R.; Hofman, M. S.; Sandhu, S.; Azad, A.; Gedye, C.; McJannett, M.; Stockler, M. R.; Davis, I. D.; Australian, New Zealand Urogenital Prostate Cancer Trials Group the Enza-p investigators

BJU International 2021 10.1111/bju.15491

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Lin, H. M.; Mak, B.; Yeung, N.; Huynh, K.; Meikle, T. G.; Mellett, N. A.; Kwan, E. M.; Fettke, H.; Tran, B.; Davis, I. D.; Mahon, K. L.; Zhang, A.; Stockler, M. R.; Briscoe, K.; Marx, G.; Crumbaker, M.; Stricker, P. D.; Du, P.; Yu, J.; Jia, S.; Scheinberg, T.; Fitzpatrick, M.; Bonnitcha, P.; Sullivan, D. R.; Joshua, A. M.; Azad, A. A.; Butler, L. M.; Meikle, P. J.; Horvath, L. G.

EBioMedicine 72 :103625, 2021 10.1016/j.ebiom.2021.103625

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer

Lin, H. M.; Yeung, N.; Hastings, J. F.; Croucher, D. R.; Huynh, K.; Meikle, T. G.; Mellett, N. A.; Kwan, E. M.; Davis, I. D.; Tran, B.; Mahon, K. L.; Zhang, A.; Stockler, M. R.; Briscoe, K.; Marx, G.; Bastick, P.; Crumbaker, M. L.; Joshua, A. M.; Azad, A. A.; Meikle, P. J.; Horvath, L. G.

Cancers 13 (19) :4964, 2021 10.3390/cancers13194964

UpFrontPSMA: a randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Dhiantravan, N.; Emmett, L.; Joshua, A. M.; Pattison, D. A.; Francis, R. J.; Williams, S.; Sandhu, S.; Davis, I. D.; Vela, I.; Neha, N.; Bressel, M.; Murphy, D. G.; Hofman, M. S.; Azad, A. A.

BJU International 128 (3) :331-342, 2021 10.1111/bju.15384

PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?

Chan, W. Y.; Brown, L. J.; Reid, L.; Joshua, A. M.

Cancers (Basel) 13 (18) :4520, 2021 10.3390/cancers13184520

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; Investigators, Enzamet Trial; the, Australian; New Zealand, Urogenital; Prostate Cancer Trials, Group

EUROPEAN UROLOGY 80 (3) :275-279, 2021 10.1016/j.eururo.2021.05.016

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Wu, S. Z.; Roden, D. L.; Al-Eryani, G.; Bartonicek, N.; Harvey, K.; Cazet, A. S.; Chan, C. L.; Junankar, S.; Hui, M. N.; Millar, E. A.; Beretov, J.; Horvath, L.; Joshua, A. M.; Stricker, P.; Wilmott, J. S.; Quek, C.; Long, G. V.; Scolyer, R. A.; Yeung, B. Z.; Segara, D.; Mak, C.; Warrier, S.; Powell, J. E.; O'Toole, S.; Lim, E.; Swarbrick, A.

Genome Medicine 13 (1) :81, 2021 10.1186/s13073-021-00885-z

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

Kwan, E. M.; Fettke, H.; Crumbaker, M.; Docanto, M. M.; To, S. Q.; Bukczynska, P.; Mant, A.; Ng, N.; Foroughi, S.; Graham, L. K.; Haynes, A. M.; Azer, S.; Lim, L. E.; Segelov, E.; Mahon, K.; Davis, I. D.; Parente, P.; Pezaro, C.; Todenhofer, T.; Sathianathen, N.; Hauser, C.; Horvath, L. G.; Joshua, A. M.; Azad, A. A.

Translational Andrology and Urology 10 (4) :1688-1699, 2021 10.21037/tau-20-1444

Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

Liang, Y.; Jeganathan, S.; Marastoni, S.; Sharp, A.; Figueiredo, I.; Marcellus, R.; Mawson, A.; Shalev, Z.; Pesic, A.; Sweet, J.; Guo, H.; Uehling, D.; Gurel, B.; Neeb, A.; He, H. H.; Montgomery, B.; Koritzinsky, M.; Oakes, S.; de Bono, J. S.; Gleave, M.; Zoubeidi, A.; Wouters, B. G.; Joshua, A. M.

CLINICAL CANCER RESEARCH 27 (8) :2340-2351, 2021 10.1158/1078-0432.CCR-20-3260

Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report

Lau, B.; Menzies, A. M.; Joshua, A. M.

Annals Of Oncology 32 (2) :280-282, 2021 10.1016/j.annonc.2020.11.006

Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer

Man, J.; Pajic, M.; Joshua, A. M.

CANCER RESEARCH 80 (22) :4886-4887, 2020 10.1158/0008-5472.CAN-20-3082

Cancer patients' experiences with immune checkpoint modulators: A qualitative study

Ala-Leppilampi, K.; Baker, N. A.; McKillop, C.; Butler, M. O.; Siu, L. L.; Spreafico, A.; Abdul Razak, A. R.; Joshua, A. M.; Hogg, D.; Bedard, P. L.; Leighl, N.; Oza, A. M.; Parsons, J. A.; Hansen, A. R.

Cancer Medicine 9 (9) :3015-3022, 2020 10.1002/cam4.2940

The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis

Crumbaker, M.; Chan, E. K. F.; Gong, T.; Corcoran, N.; Jaratlerdsiri, W.; Lyons, R. J.; Haynes, A. M.; Kulidjian, A. A.; Kalsbeek, A. M. F.; Petersen, D. C.; Stricker, P. D.; Jamieson, C. A. M.; Croucher, P. I.; Hovens, C. M.; Joshua, A. M.; Hayes, V. M.

Cancers 12 (5) :1178, 2020 10.3390/cancers12051178

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

Scheinberg, T.; Kench, J.; Stockler, M.; Mahon, K. L.; Sebastian, L.; Stricker, P.; Joshua, A. M.; Woo, H.; Thanigasalam, R.; Ahmadi, N.; Centenera, M. M.; Butler, L. M.; Horvath, L. G.

BMJ Open 10 (1) :e033667, 2020 10.1136/bmjopen-2019-033667

Developing a pan-cancer research autopsy programme

Bavi, P.; Siva, M.; Abi-Saab, T.; Chadwick, D.; Dhani, N.; Butany, J.; Joshua, A. M.; Roehrl, M. H.

JOURNAL OF CLINICAL PATHOLOGY 72 (10) :689-695, 2019 10.1136/jclinpath-2019-205874